{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2","upperLimit":"94","value":"16"},{"groupId":"OG001","lowerLimit":"3","upperLimit":"88","value":"9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"description":"Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions","dispersionType":"Full Range","groups":[{"description":"All patients will receive 4 cycles of clarithromycin 500mg twice daily on days 1-28, pomalidomide 4 mg daily on days 1 through 21 and dexamethasone orally at a dose of 40 mg daily on days 1, 8, 15, and 22 of each 28-day cycle. Patients randomized to auto-SCT will proceed within 28 days after completion of the 4th cycle of ClaPD to receive melphalan 140mg/m2 or 200mg/m2 (as per institutional guidelines) followed by hematopoietic cell infusion.\n\nPomalidomide\n\nstem cell\n\nClarithromycin","id":"OG000","title":"Clarithromycin + Pomalidomide + Dexamethasone + Stem Cell"},{"description":"All patients will receive 4 cycles of clarithromycin 500mg twice daily on days 1-28 pomalidomide 4 mg daily on days 1 through 21 and dexamethasone orally at a dose of 40 mg daily on days 1, 8, 15, and 22 of each 28 day cycle. Patients assigned to ClaPD alone will receive 5 additional cycles of ClaPD.\n\nPomalidomide\n\nDexamethasone\n\nClarithromycin","id":"OG001","title":"Clarithromycin + Pomalidomide + Dexamethasone Alone"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"up to 94 months","title":"Progression Free Survival","type":"SECONDARY","unitOfMeasure":"months"}